Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  Samsung Biologics Co.,Ltd.    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
686000 682000 688000 658000 636000 Last
58814 81698 46849 186601 196976 Volume
-0.15% -0.58% +0.88% -4.36% -3.34% Change
Financials
Sales 2019 602 B 0,53 B 0,53 B
Net income 2019 44,8 B 0,04 B 0,04 B
Net cash position 2019 237 B 0,21 B 0,21 B
P/E ratio 2019 1 007x
Yield 2019 0,01%
Sales 2020 1 047 B 0,92 B 0,92 B
Net income 2020 227 B 0,20 B 0,20 B
Net cash position 2020 252 B 0,22 B 0,22 B
P/E ratio 2020 192x
Yield 2020 -
Capitalization 43 537 B 38 341 M 38 399 M
EV / Sales 2019 72 324x
EV / Sales 2020 41 584x
Nbr of Employees 2 534
Free-Float 24,9%
More Financials
Company
SAMSUNG BIOLOGICS CO.,LTD. is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, as a contract manufacturing organization (CMO), mainly develops, manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. It also provides cell line development and process development services. The Company... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Notations Surperformance© of Samsung Biologics Co.,Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about SAMSUNG BIOLOGICS CO.,LTD.
10/22Trial begins in Samsung leader Jay Y. Lee's suspected fraud, stock manipulati..
RE
10/06EMA Accepts Biogen, Samsung Bioepis Filing for Lucentis Biosimilar
DJ
09/03Samsung's Future Includes a $2 Billion 'Super Plant' -- Update
DJ
09/03Samsung's Drugmaking Future Includes a $2 Billion 'Super Plant' Bigger Than t..
DJ
09/01Samsung leader Jay Y. Lee indicted in South Korea on allegations linked to 20..
RE
09/01SAMSUNG ELECTRONICS : Lee indicted over controversial 2015 merger
AQ
09/01REFILE-UPDATE 3-Samsung leader Jay Y. Lee indicted in S.Korea on allegations ..
RE
07/04Lee Jae-yong admitted in 2016 to have received reports of unfair merger betwe..
AQ
06/26Samsung group heir should not be indicted, South Korea panel recommends
RE
06/11OUTSIDE PANEL TO REVIEW SAMSUNG HEIR : Seoul prosecutors
RE
06/11Outside panel to review Samsung heir Lee's case - Seoul prosecutors
RE
06/09Samsung's Lee Avoids Arrest Warrant -- WSJ
DJ
06/08South Korean court denies arrest warrant request for Samsung heir
RE
06/08South Korean court denies arrest warrant request for Samsung heir
RE
06/08South Korean Court Denies Arrest Warrant for Samsung's Lee Jae-Yong -- Update
DJ
More news
News in other languages on SAMSUNG BIOLOGICS CO.,LTD.
06/04Samsung-Erbe Lee droht wegen Manipulationsvorwürfen die Verhaftung
05/26Samsung-Erbe Lee wird wegen umstrittener Firmenfusion vernommen
2019CORÉE DU SUD : mandats d'arrêt contre deux vice-présidents de Samsung Electronic..
2018Résumé des principales informations économiques du mercredi 14 novembre 2018
2018Samsung BioLogics accusé de 4 milliards de dollars d'irrégularités comptables
More news
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 658 000,00 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Tae-Han Kim Chief Executive Officer & Director
Ho-Yeol Yoon Managing Director & Head-Operations Support
James J. Choi Managing Director & Head-Information Technology
Yong-Ho An Managing Director & Head-Process Technology
Dong-Joong Kim Director & Head-Management Support
Sector and Competitors
1st jan.Capitalization (M$)
SAMSUNG BIOLOGICS CO.,LTD.51.96%38 341
CSL LIMITED7.46%95 866
BIOGEN INC.-10.09%41 056
WUXI BIOLOGICS (CAYMAN) INC.126.25%39 118
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.208.12%36 623
ALEXION PHARMACEUTICALS, INC.9.28%26 228